A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors - Trial NCT06368921
Access comprehensive clinical trial information for NCT06368921 through Pure Global AI's free database. This Phase 1 trial is sponsored by Guangzhou Virotech Pharmaceutical Co., Ltd. and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Guangzhou Virotech Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 1
Apr 01, 2024
Dec 01, 2025
Primary Outcome
Evaluate the safety and tolerability of escalating doses of intratumoral injection of VRT106.,Characterize the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) levels.
Summary
To Evaluate the safety and tolerability of single and multiple intratumoral injections of
 recombinant oncolytic virus M1 (VRT106) in patients with locally advanced/metastatic solid
 tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06368921
Non-Device Trial